Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired BioAge Labs, Inc. (“BioAge”) (NASDAQ: BIOA) common stock pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with the initial public offering (“IPO”) on or about September 26, 2024.
The Class Period begins on September 26, 2024, when BioAge filed its final prospectus for the company’s IPO, which was incorporated into the registration statement, and listed for sale 11 million shares of BioAge common stock at an offering price of $18 per share. BioAge’s final prospectus for the IPO represented the significance and benefits of azelaprag for the treatment of obesity in older adults. Specifically, BioAge touted azelaprag in connection with the company’s ongoing STRIDES Phase 2 trial and represented that there were no safety concerns and that BioAge expected top line results to meet its primary endpoint goals in connection with its STRIDES clinical trial.
The complaint alleges that, in the Offering Documents, Defendants made false and/or misleading statements and/or failed to disclose information pertinent to investors concerning BioAge’s STRIDES Phase 2 trial for azelaprag. Specifically, Defendants misrepresented and/or failed to disclose: (1) the potential for liver transaminitis in any of its previous clinical STRIDES Phase 1 trials and various preclinical tox studies; (2) that there were no safety concerns and that BioAge expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On March 2, 2026, the Court granted Defendants’ Motion to Dismiss the Amended Complaint. This action has concluded.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.